<?xml version="1.0" encoding="ISO-8859-1"?><article xmlns:mml="http://www.w3.org/1998/Math/MathML" xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:xsi="http://www.w3.org/2001/XMLSchema-instance">
<front>
<journal-meta>
<journal-id>0300-9041</journal-id>
<journal-title><![CDATA[Ginecología y obstetricia de México]]></journal-title>
<abbrev-journal-title><![CDATA[Ginecol. obstet. Méx.]]></abbrev-journal-title>
<issn>0300-9041</issn>
<publisher>
<publisher-name><![CDATA[Federación Mexicana de Colegios de Obstetricia y Ginecología A.C.]]></publisher-name>
</publisher>
</journal-meta>
<article-meta>
<article-id>S0300-90412020000500312</article-id>
<article-id pub-id-type="doi">10.24245/gom.v88i5.3555</article-id>
<title-group>
<article-title xml:lang="es"><![CDATA[Supervivencia a 5 años de pacientes con cáncer de mama: experiencia en una institución de Jalisco, México]]></article-title>
<article-title xml:lang="en"><![CDATA[Breast cancer survival at 5 years: Experience of an institution at Jalisco, México]]></article-title>
</title-group>
<contrib-group>
<contrib contrib-type="author">
<name>
<surname><![CDATA[Dorado-Roncancio]]></surname>
<given-names><![CDATA[Elkin Fabián]]></given-names>
</name>
<xref ref-type="aff" rid="Aff"/>
</contrib>
<contrib contrib-type="author">
<name>
<surname><![CDATA[Vázquez-Nares]]></surname>
<given-names><![CDATA[Jose Jaime]]></given-names>
</name>
<xref ref-type="aff" rid="Aff"/>
</contrib>
<contrib contrib-type="author">
<name>
<surname><![CDATA[Hernandez-Garibay]]></surname>
<given-names><![CDATA[César Augusto]]></given-names>
</name>
<xref ref-type="aff" rid="Aff"/>
</contrib>
<contrib contrib-type="author">
<name>
<surname><![CDATA[García González]]></surname>
<given-names><![CDATA[Ilian Janet]]></given-names>
</name>
<xref ref-type="aff" rid="Aff"/>
</contrib>
</contrib-group>
<aff id="Af1">
<institution><![CDATA[,Instituto Jalisciense de Cancerología  ]]></institution>
<addr-line><![CDATA[Guadalajara Jalisco]]></addr-line>
<country>Mexico</country>
</aff>
<aff id="Af2">
<institution><![CDATA[,Instituto Jalisciense de Cancerología Clínica de Mama ]]></institution>
<addr-line><![CDATA[Guadalajara Jalisco]]></addr-line>
<country>Mexico</country>
</aff>
<aff id="Af3">
<institution><![CDATA[,Instituto Jalisciense de Cancerología  ]]></institution>
<addr-line><![CDATA[Guadalajara Jalisco]]></addr-line>
<country>Mexico</country>
</aff>
<pub-date pub-type="pub">
<day>00</day>
<month>00</month>
<year>2020</year>
</pub-date>
<pub-date pub-type="epub">
<day>00</day>
<month>00</month>
<year>2020</year>
</pub-date>
<volume>88</volume>
<numero>5</numero>
<fpage>312</fpage>
<lpage>320</lpage>
<copyright-statement/>
<copyright-year/>
<self-uri xlink:href="http://www.scielo.org.mx/scielo.php?script=sci_arttext&amp;pid=S0300-90412020000500312&amp;lng=en&amp;nrm=iso"></self-uri><self-uri xlink:href="http://www.scielo.org.mx/scielo.php?script=sci_abstract&amp;pid=S0300-90412020000500312&amp;lng=en&amp;nrm=iso"></self-uri><self-uri xlink:href="http://www.scielo.org.mx/scielo.php?script=sci_pdf&amp;pid=S0300-90412020000500312&amp;lng=en&amp;nrm=iso"></self-uri><abstract abstract-type="short" xml:lang="es"><p><![CDATA[Resumen:  OBJETIVO: Determinar la supervivencia a 5 años (global y libre de enfermedad) posterior al tratamiento de pacientes con cáncer de mama atendidas en el Instituto Jalisciense de Cancerología.  MATERIALES Y MÉTODOS:  Estudio observacional, descriptivo, transversal y retrospectivo efectuado en pacientes con diagnóstico de cáncer de mama atendidas en el trascurso del año 2013 en la Clínica de Mama del Instituto Jalisciense de Cancerología, Guadalajara. La supervivencia global y libre de enfermedad a 5 años se estableció a partir del tiempo trascurrido desde el diagnóstico hasta la ocurrencia de recidiva, metástasis, muerte o fecha del último contacto, con límite a diciembre de 2018.  RESULTADOS: Se revisaron 311 expedientes pero solo se analizaron 172. La edad promedio al diagnóstico fue de 51.4 años. La etapa más repetida fue la IIIA, determinada en 64 pacientes (37.2%), IIA en 38 pacientes (22.1%), IIB en 19 pacientes (11.0%), IA y IIIC cada una con 15 pacientes (8.7%). La probabilidad de supervivencia global a cinco años fue de 78.5%. El 24.4% tuvo recurrencia, con una media de supervivencia de 46.8 meses. Se demostró significación estadística entre la etapa, grado histológico, reporte inmunohistoquímico e invasión ganglionar y la supervivencia.  CONCLUSIONES: Esta investigación representa un esfuerzo para lograr establecer la supervivencia a cinco años de nuestras pacientes. En la población estudiada, la supervivencia tuvo valores aceptables y equiparables con otros estudios nacionales e internacionales y refleja la buena práctica médica de nuestra institución.]]></p></abstract>
<abstract abstract-type="short" xml:lang="en"><p><![CDATA[Abstract:  OBJECTIVE: To determine the 5-year survival (global and disease-free) after the treatment of patients with breast cancer at the Instituto Jalisciense de Cancerología.  MATERIALS AND METHODS:  Observational, descriptive cross-sectional, retrospective study of patients diagnosed with breast cancer treated during 2013 in the breast clinic service of the Instituto Jalisciense de Cancerología, Guadalajara. The five-year global and disease-free survival was established from the time elapsed from the diagnosis until the occurrence of an event (recurrence, metastasis or death) or date of last contact, with a limit to December 2018.  RESULT:  311 files were reviewed, but only 172 were included for the analysis of overall survival and disease-free survival at five years. The average age at diagnosis was 51.4 years. The most repeated stage was IIIA, determined in 64 patients (37.4%), IIA in 38 patients (22.2%), IIB in 19 patients (11.1%), AI and IIIC each with 15 patients (8.8%). The probability of five-year global survival was 78.5%. 24.4% presented recurrence with an average survival of 46.8 months. Statistical significance was demonstrated between stage, histological grade, result of immunohistochemistry and lymph node invasion and survival.  CONCLUSIONS:  This research represents an effort to establish the five-year survival of our patients. In the population studied, survival had acceptable and comparable values with other national and international studies and reflects the good medical practice of our institution.]]></p></abstract>
<kwd-group>
<kwd lng="es"><![CDATA[Cáncer de mama]]></kwd>
<kwd lng="es"><![CDATA[supervivencia libre de enfermedad]]></kwd>
<kwd lng="es"><![CDATA[inmunohistoquímica]]></kwd>
<kwd lng="es"><![CDATA[neoplasias mamarias]]></kwd>
<kwd lng="es"><![CDATA[nodos linfáticos]]></kwd>
<kwd lng="en"><![CDATA[Breast Cancer]]></kwd>
<kwd lng="en"><![CDATA[Disease-Free Survival]]></kwd>
<kwd lng="en"><![CDATA[Immunohistochemistry]]></kwd>
<kwd lng="en"><![CDATA[Breast Neoplasms]]></kwd>
<kwd lng="en"><![CDATA[Lymph Nodes]]></kwd>
</kwd-group>
</article-meta>
</front><back>
<ref-list>
<ref id="B1">
<label>1</label><nlm-citation citation-type="book">
<collab>Global Cancer Observatory, Globocan</collab>
<source><![CDATA[]]></source>
<year>2018</year>
<publisher-loc><![CDATA[Mexico ]]></publisher-loc>
<publisher-name><![CDATA[Global Cancer Observatory]]></publisher-name>
</nlm-citation>
</ref>
<ref id="B2">
<label>2</label><nlm-citation citation-type="">
<collab>Instituto Nacional de Estadísticas y Geografía, INEGI</collab>
<source><![CDATA[]]></source>
<year>2014</year>
</nlm-citation>
</ref>
<ref id="B3">
<label>3</label><nlm-citation citation-type="journal">
<collab>National Cancer Institute</collab>
<article-title xml:lang=""><![CDATA[Cancer of the Female Breast (Invasive)]]></article-title>
<source><![CDATA[SEER Cancer Statistics Review1975-2014]]></source>
<year>2018</year>
</nlm-citation>
</ref>
<ref id="B4">
<label>4</label><nlm-citation citation-type="journal">
<person-group person-group-type="author">
<name>
<surname><![CDATA[Jonathan]]></surname>
<given-names><![CDATA[Berek]]></given-names>
</name>
<name>
<surname><![CDATA[Neville]]></surname>
<given-names><![CDATA[Hacker]]></given-names>
</name>
</person-group>
<article-title xml:lang=""><![CDATA[Gynecologic Oncology]]></article-title>
<source><![CDATA[Wolters Kluwer]]></source>
<year>2015</year>
<edition>6</edition>
</nlm-citation>
</ref>
<ref id="B5">
<label>5</label><nlm-citation citation-type="journal">
<person-group person-group-type="author">
<name>
<surname><![CDATA[Sun]]></surname>
<given-names><![CDATA[YS]]></given-names>
</name>
</person-group>
<article-title xml:lang=""><![CDATA[Risk factors and preventions of breast cancer]]></article-title>
<source><![CDATA[Int J Biol Sci]]></source>
<year>2017</year>
<volume>13</volume>
<numero>11</numero>
<issue>11</issue>
<page-range>1387-97</page-range></nlm-citation>
</ref>
<ref id="B6">
<label>6</label><nlm-citation citation-type="journal">
<person-group person-group-type="author">
<name>
<surname><![CDATA[Nelson]]></surname>
<given-names><![CDATA[HD]]></given-names>
</name>
</person-group>
<article-title xml:lang=""><![CDATA[Risk factors for breast cancer for women age 40 to 49: A systematic review and meta-analysis]]></article-title>
<source><![CDATA[Ann Intern Med]]></source>
<year>2012</year>
<volume>156</volume>
<numero>9</numero>
<issue>9</issue>
<page-range>635-48</page-range></nlm-citation>
</ref>
<ref id="B7">
<label>7</label><nlm-citation citation-type="journal">
<person-group person-group-type="author">
<name>
<surname><![CDATA[Kandil]]></surname>
<given-names><![CDATA[MA]]></given-names>
</name>
</person-group>
<article-title xml:lang=""><![CDATA[Study of prognostic and predictive factors in locally advanced breast cancer in Egypt]]></article-title>
<source><![CDATA[Menoufia Med]]></source>
<year>2018</year>
<volume>31</volume>
<page-range>339-47</page-range></nlm-citation>
</ref>
<ref id="B8">
<label>8</label><nlm-citation citation-type="journal">
<person-group person-group-type="author">
<name>
<surname><![CDATA[Rodríguez-Cuevas]]></surname>
<given-names><![CDATA[S]]></given-names>
</name>
</person-group>
<article-title xml:lang=""><![CDATA[Breast carcinoma presents a decade earlier in Mexican women than in women in the United States or European countries]]></article-title>
<source><![CDATA[Cancer]]></source>
<year>2001</year>
<volume>91</volume>
<page-range>863-8</page-range></nlm-citation>
</ref>
<ref id="B9">
<label>9</label><nlm-citation citation-type="">
<collab>NIH</collab>
<source><![CDATA[Cancer Stat Facts: Female Breast Cancer]]></source>
<year></year>
</nlm-citation>
</ref>
<ref id="B10">
<label>10</label><nlm-citation citation-type="journal">
<person-group person-group-type="author">
<name>
<surname><![CDATA[Allemani]]></surname>
<given-names><![CDATA[C]]></given-names>
</name>
</person-group>
<article-title xml:lang=""><![CDATA[Breast cancer survival in the US and Europe: a CONCORD high-resolution study]]></article-title>
<source><![CDATA[Int J Cancer]]></source>
<year>2013</year>
<volume>132</volume>
<numero>5</numero>
<issue>5</issue>
<page-range>1170-8</page-range></nlm-citation>
</ref>
<ref id="B11">
<label>11</label><nlm-citation citation-type="">
<collab>Cancer Research UK</collab>
<source><![CDATA[Breast cancer five-year net survival by stage, with incidence by stage (all data: adults diagnosed 2013-2017, followed up to 2018)]]></source>
<year></year>
</nlm-citation>
</ref>
<ref id="B12">
<label>12</label><nlm-citation citation-type="journal">
<person-group person-group-type="author">
<name>
<surname><![CDATA[Perou]]></surname>
<given-names><![CDATA[C]]></given-names>
</name>
</person-group>
<article-title xml:lang=""><![CDATA[Molecular Portraits of Human Breast Tumors]]></article-title>
<source><![CDATA[Nature]]></source>
<year>2000</year>
<volume>406</volume>
<page-range>747-52</page-range></nlm-citation>
</ref>
<ref id="B13">
<label>13</label><nlm-citation citation-type="book">
<person-group person-group-type="author">
<name>
<surname><![CDATA[Ries]]></surname>
<given-names><![CDATA[LG]]></given-names>
</name>
</person-group>
<article-title xml:lang=""><![CDATA[Chapter 13 - Cancer of the female breast]]></article-title>
<person-group person-group-type="editor">
<name>
<surname><![CDATA[Ries]]></surname>
<given-names><![CDATA[LG]]></given-names>
</name>
<name>
<surname><![CDATA[Young]]></surname>
<given-names><![CDATA[JL]]></given-names>
</name>
<name>
<surname><![CDATA[Keel]]></surname>
<given-names><![CDATA[GE]]></given-names>
</name>
<name>
<surname><![CDATA[Eisner]]></surname>
<given-names><![CDATA[MP]]></given-names>
</name>
<name>
<surname><![CDATA[Lin]]></surname>
<given-names><![CDATA[YD]]></given-names>
</name>
<name>
<surname><![CDATA[Horner]]></surname>
<given-names><![CDATA[M-J]]></given-names>
</name>
</person-group>
<source><![CDATA[SEER Survival Monograph: Cancer survival among adults: US SEER Program, 1988-2001, patient and tumor characteristics]]></source>
<year>2007</year>
<publisher-loc><![CDATA[Bethesda, MD ]]></publisher-loc>
<publisher-name><![CDATA[National Cancer Institute]]></publisher-name>
</nlm-citation>
</ref>
<ref id="B14">
<label>14</label><nlm-citation citation-type="journal">
<person-group person-group-type="author">
<name>
<surname><![CDATA[Kim]]></surname>
<given-names><![CDATA[YY]]></given-names>
</name>
</person-group>
<article-title xml:lang=""><![CDATA[Prognostically distinctive subgroup in pathologic N3 breast cancer]]></article-title>
<source><![CDATA[J Breast Cancer]]></source>
<year>2016</year>
<volume>19</volume>
<numero>2</numero>
<issue>2</issue>
<page-range>163-8</page-range></nlm-citation>
</ref>
</ref-list>
</back>
</article>
